Location Directory

Clinical trials in Nashville, Tennessee

This page shows live ClinicalTrials.gov search results for Nashville, Tennessee, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10880

Shown on this page

Current sort

Institutions in Nashville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Vanderbilt University Medical Center

Live official records

Open in full search

Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 78
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more

Conditions: Urothelial Cancer, Urinary Bladder Neoplasms
Interventions: Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab; Drug · Radiation
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 21
States / cities: Little Rock, Arkansas • Santa Barbara, California • Aurora, Colorado + 18 more

Conditions: Glycogen Storage Disease Type II, Pompe Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2034
U.S. locations: 98
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more

Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 22
States / cities: Irvine, California • Orange, California • Gainesville, Florida + 14 more

Conditions: Peanut Allergy
Interventions: DBV712 250 mcg; Biological
Lead sponsor: DBV Technologies; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 26
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more

Conditions: Cancer
Interventions: Darolutamide (Nubeqa, BAY1841788); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 36
States / cities: Homewood, Alabama • Chandler, Arizona • Los Angeles, California + 31 more

Conditions: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Interventions: Ivosidenib 500mg, Placebo; Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 22
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 19 more

Conditions: Malignant Solid Tumors
Interventions: TAK-505; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 15
States / cities: Orange, California • San Diego, California • San Francisco, California + 10 more

Conditions: Neoplasms, Ovarian
Interventions: MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Sacramento, California • San Francisco, California • Whittier, California + 7 more

Conditions: Parkinson Disease
Interventions: AP-472, Placebo; Drug · Other
Lead sponsor: Appello Pharmaceuticals, Inc.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more

Conditions: Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Iadademstat; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 32
States / cities: Irvine, California • Orange, California • Palo Alto, California + 28 more

Conditions: Advanced Solid Tumor
Interventions: STX-003, KEYTRUDA®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee

Clinical trials in Nashville, Tennessee

Filter and sort this location

Institutions in Nashville

Live official records

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Pompe Disease Registry Protocol

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

A Study of TAK-505 in Adults With Solid Tumors

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab